GENSIGHT BIOLOGICS SA (SIGHT.PA) Stock Fundamental Analysis

EPA:SIGHT • FR0013183985

0.0885 EUR
+0 (+1.72%)
Last: Feb 27, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership
Fundamental Rating

1

Taking everything into account, SIGHT scores 1 out of 10 in our fundamental rating. SIGHT was compared to 77 industry peers in the Biotechnology industry. Both the profitability and financial health of SIGHT have multiple concerns. SIGHT is valied quite expensively at the moment, while it does show a decent growth rate.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • SIGHT had negative earnings in the past year.
  • SIGHT had a negative operating cash flow in the past year.
  • SIGHT had negative earnings in each of the past 5 years.
  • In the past 5 years SIGHT always reported negative operating cash flow.
SIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFSIGHT.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 -10M -20M -30M

1.2 Ratios

  • SIGHT has a Return On Assets of -205.69%. This is amonst the worse of the industry: SIGHT underperforms 89.61% of its industry peers.
Industry RankSector Rank
ROA -205.69%
ROE N/A
ROIC N/A
ROA(3y)-174.59%
ROA(5y)-129.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
SIGHT.PA Yearly ROA, ROE, ROICSIGHT.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 100 -100 -200

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for SIGHT so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
SIGHT.PA Yearly Profit, Operating, Gross MarginsSIGHT.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • SIGHT does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • The number of shares outstanding for SIGHT has been increased compared to 1 year ago.
  • The number of shares outstanding for SIGHT has been increased compared to 5 years ago.
  • The debt/assets ratio for SIGHT has been reduced compared to a year ago.
SIGHT.PA Yearly Shares OutstandingSIGHT.PA Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
SIGHT.PA Yearly Total Debt VS Total AssetsSIGHT.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

2.2 Solvency

  • SIGHT has an Altman-Z score of -56.55. This is a bad value and indicates that SIGHT is not financially healthy and even has some risk of bankruptcy.
  • SIGHT's Altman-Z score of -56.55 is on the low side compared to the rest of the industry. SIGHT is outperformed by 85.71% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -56.55
ROIC/WACCN/A
WACC5.15%
SIGHT.PA Yearly LT Debt VS Equity VS FCFSIGHT.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M

2.3 Liquidity

  • SIGHT has a Current Ratio of 0.11. This is a bad value and indicates that SIGHT is not financially healthy enough and could expect problems in meeting its short term obligations.
  • With a Current ratio value of 0.11, SIGHT is not doing good in the industry: 94.81% of the companies in the same industry are doing better.
  • A Quick Ratio of 0.11 indicates that SIGHT may have some problems paying its short term obligations.
  • SIGHT's Quick ratio of 0.11 is on the low side compared to the rest of the industry. SIGHT is outperformed by 94.81% of its industry peers.
Industry RankSector Rank
Current Ratio 0.11
Quick Ratio 0.11
SIGHT.PA Yearly Current Assets VS Current LiabilitesSIGHT.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. Growth

3.1 Past

  • SIGHT shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 78.83%, which is quite impressive.
  • SIGHT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -91.76%.
  • The Revenue has been growing by 16.47% on average over the past years. This is quite good.
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.2%
Revenue 1Y (TTM)-91.76%
Revenue growth 3Y-34.24%
Revenue growth 5Y16.47%
Sales Q2Q%-120.15%

3.2 Future

  • Based on estimates for the next years, SIGHT will show a very negative growth in Earnings Per Share. The EPS will decrease by -27.07% on average per year.
  • SIGHT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 102.12% yearly.
EPS Next Y-2.06%
EPS Next 2Y-35.46%
EPS Next 3Y-27.07%
EPS Next 5YN/A
Revenue Next Year-3.66%
Revenue Next 2Y-9.13%
Revenue Next 3Y102.12%
Revenue Next 5YN/A

3.3 Evolution

  • The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
SIGHT.PA Yearly Revenue VS EstimatesSIGHT.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 10M 20M 30M
SIGHT.PA Yearly EPS VS EstimatesSIGHT.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 -0.2 -0.4 -0.6 -0.8 -1

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for SIGHT. In the last year negative earnings were reported.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for SIGHT. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
SIGHT.PA Price Earnings VS Forward Price EarningsSIGHT.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
SIGHT.PA Per share dataSIGHT.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.2 -0.4 -0.6 -0.8

4.3 Compensation for Growth

  • SIGHT's earnings are expected to decrease with -27.07% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-35.46%
EPS Next 3Y-27.07%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • SIGHT does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GENSIGHT BIOLOGICS SA

EPA:SIGHT (2/27/2026, 7:00:00 PM)

0.0885

+0 (+1.72%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-07
Earnings (Next)03-26
Inst Owners26.05%
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap19.55M
Revenue(TTM)194.00K
Net Income(TTM)-15.12M
Analysts80
Price Target0.44 (397.18%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)-57.98%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-25.53%
Revenue NY rev (3m)-25.53%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 100.77
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.13
EYN/A
EPS(NY)-0.92
Fwd EYN/A
FCF(TTM)-0.04
FCFYN/A
OCF(TTM)-0.04
OCFYN/A
SpS0
BVpS-0.15
TBVpS-0.15
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -205.69%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-174.59%
ROA(5y)-129.22%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.03
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 0%
Cap/Sales 0%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.11
Quick Ratio 0.11
Altman-Z -56.55
F-Score3
WACC5.15%
ROIC/WACCN/A
Cap/Depr(3y)8.1%
Cap/Depr(5y)5.68%
Cap/Sales(3y)3.54%
Cap/Sales(5y)2.27%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)78.83%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%23.2%
EPS Next Y-2.06%
EPS Next 2Y-35.46%
EPS Next 3Y-27.07%
EPS Next 5YN/A
Revenue 1Y (TTM)-91.76%
Revenue growth 3Y-34.24%
Revenue growth 5Y16.47%
Sales Q2Q%-120.15%
Revenue Next Year-3.66%
Revenue Next 2Y-9.13%
Revenue Next 3Y102.12%
Revenue Next 5YN/A
EBIT growth 1Y59.36%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.62%
EBIT Next 3Y10.85%
EBIT Next 5YN/A
FCF growth 1Y75.87%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y75.8%
OCF growth 3YN/A
OCF growth 5YN/A

GENSIGHT BIOLOGICS SA / SIGHT.PA FAQ

What is the fundamental rating for SIGHT stock?

ChartMill assigns a fundamental rating of 1 / 10 to SIGHT.PA.


What is the valuation status of GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?

ChartMill assigns a valuation rating of 0 / 10 to GENSIGHT BIOLOGICS SA (SIGHT.PA). This can be considered as Overvalued.


How profitable is GENSIGHT BIOLOGICS SA (SIGHT.PA) stock?

GENSIGHT BIOLOGICS SA (SIGHT.PA) has a profitability rating of 0 / 10.


Can you provide the financial health for SIGHT stock?

The financial health rating of GENSIGHT BIOLOGICS SA (SIGHT.PA) is 0 / 10.


What is the earnings growth outlook for GENSIGHT BIOLOGICS SA?

The Earnings per Share (EPS) of GENSIGHT BIOLOGICS SA (SIGHT.PA) is expected to decline by -2.06% in the next year.